The 2021 Translational Medicine Symposium is co-sponsored by the Program in Translational Medicine and the Cancer Cell Biology Training Program. This year’s symposium will include Zoom sessions and Gathertown spaces.

Register

Join a live training session for the N3C Data Enclave. Users of all types can learn how to navigate the N3C, utilize the Enclave and resources it provides, and learn how to better achieve their analytical goals. This orientation is split into 2 sessions – Session A and Session B. These orientations are ongoing and will alternate week by week. Session A is recommended before attending Session B

Session B is for analysts, statisticians, data scientists, or anyone who wants to gain a broader understanding of the tools needed to work with the data.

Topics include:

• Focus on technical aspects of working with data in the secure N3C Enclave, including use of OMOP concept sets and N3C-specific tooling, such as the Concept Set Browser.
• Introduce commonly used analysis tools, such as Contour and Code Workbooks and corresponding workflows for simple analyses.
• Introduce the Enclave Knowledge Store, a mechanism for sharing and using community-developed code and data across projects.

Note: This orientation is held alternating Tuesdays | 8-9:30am PT/11am-12:30pm ET

Register

Implementation Science in Global Health: Leveraging the Power of Community

Join NC TraCS and the Center for AIDS Research for the Spring 2021 edition of the Implementation Science Speaker Series, featuring Carolyn Audet, PhD, Assistant Professor of Health Policy and Epidemiology and Assistant Director of Community Based Implementation Research at Vanderbilt University.

In this seminar, Audet will discuss engagement of traditional healers in the delivery of evidence-based HIV testing and treatment support in rural South Africa. She will cover the process of adapting evidence-based interventions; assessing strategy acceptability, feasibility and appropriateness; and documentation of implementation fidelity. Finally, Audet will share about the benefits of creating strong relationships with study communities and the obligations researchers have to their in-country partners.

Presenter

Carolyn Audet, PhD
Assistant Professor, Vanderbilt University

Register

This six-part orientation is strongly recommended for all clinical research personnel who are new to UNC or new to research. The series will introduce research personnel to the UNC offices involved in clinical trials, discuss the federal and local regulations governing conduct of research, and provide an overview of best practices utilized in the implementation of clinical research. It is recommended that registrants complete both the CITI Good Clinical Practice (GCP) and CITI Human Subjects Protection (IRB/Ethics) modules prior to attending the orientation.

Each session of the orientation will be held on Wednesday afternoons,1:30 to 4:30 pm. Research personnel are encouraged to attend all 6 modules, but may choose to attend only those of particular interest or relevance. The topics to be covered this week include:

• Contracts and Clinical Trial Agreements (Vonzell Jones) - 1:30 pm - 2:10 pm
• Billing Coverage Analysis overview (Andrea Eiring ) - 2:10 pm - 2:50 pm
• Budgeting for Clinical Research, Accounting of Funds (Jill Cunnup) - 2:55 pm - 3:15 pm
• Preparing and Executing NIH Grant Budgets (Sandy Barnhart) - 3:15 pm - 4:00 pm
• Post-Session Q&A Discussion 4:00 pm - 4:30 pm

Register

CTSA Visiting Scholar — Therapeutic Advances in Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia (HHT) is a rare, hereditary multisystem vascular disease of disordered angiogenesis. Pathologic elevations in vascular endothelial growth factor (VEGF) result in fragile, abnormal vessels in nasal and GI mucosa leading to chronic epistaxis and GI bleeding, anemia that is frequently severe and transfusion-dependent, and diminished quality of life.

Bevacizumab is a recombinant, humanized monoclonal IgG1 antibody that neutralizes circulating VEGF and is a potential targeted therapy in HHT. Hanny Al-Samkari, MD will describe the revolutionary potential of anti-angiogenic therapy in HHT and the evidence to date for systemic bevacizumab as a treatment for bleeding and anemia in HHT.

Presenter:
Hanny Al-Samkari, MD
Division of Hematology/Oncology, Massachusetts General Hospital
Instructor in Medicine and KL2 Scholar, Harvard Medical School

Register